About us

Glycotope is a clinical-stage immuno-oncology company built on world-leading glyco-biology expertise. The company draws on its long experience in glyco-biology to create highly specific mAbs targeting glyco-epitopes, and glyco-optimized mAbs with enhanced performance.

Glycotope has a growing pipeline of high-value cancer therapies focused around the antibody gatipotuzumab, which targets the novel glyco-epitope target TA-MUC1. Its lead clinical program is in Phase Ib in combination with Tomuzotuximab, a glyco-optimized second-generation anti-EGFR mAb.

In addition the company has a mature and growing pipeline of proprietary cancer therapies incl. PM-CD3-GEX® - a bispecific T cell engaging antibody recognizing tumor-specific TA-MUC1 on tumor cells and a specific receptor (CD3) on T cells and PM-IL15-GEX® - a TA-MUC1 targeting antibody fused to the cytokine Interleukin-15 to turn the immune desert at the tumor site into an immunologically hot tumor to induce tumor killing.

Products and services

Glycotope provides a wide range of services for biopharmaceutical companies incl.

  • Glycoanalytical / PTM-analytical service

  • Cell line development in CHO / GEX cell lines

  • Process development (USP and DSP)

  • Assay development

  • Immunomonitoring

    Our innovative GlycoExpress® technology enables the generation of high quality oncology and non-oncology candidates with fully human glycosylation improving activity, drug characteristics and side effect profiles.

Address
Glycotope GmbH
Robert-Roessle-Str. 10
13125 Berlin
Germany

Phone: +49 30 94892600
Internet: www.glycotope.com
E-mail: Send message

Contact person

Lars Stoeckl
Director BD
Phone: +49 1761 9489823
E-mail: Send message

Click here if you notice an image that violates copyright or privacy rights.

Get in contact
OK

We use cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection